Synthon Hispania, S.L. (division responsible for full production cycle)

The drug is prescribed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have specific activating mutations of the epidermal growth factor receptor (EGFR).

Dosage form: tablets, film-coated

ATC: L01XE02